Clinical studies of extended-half-life recombinant FVIII products for prophylaxis in adults and children: a critical review from the physician's perspective.
Sign Up to like & getrecommendations! Published in 2022 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2022.103678
Abstract: This review compares the methodology of published clinical studies investigating the extended-half-life (EHL) factor VIII (FVIII) products, rFVIIIFc (efmoroctocog alfa, Elocta®/Eloctate®), BAY 94-9027 (damoctocog alfa pegol, Jivi®), BAX 855 (rurioctocog alfa pegol, Adynovate®) and N8-GP… read more here.
Keywords: clinical studies; methodology; fviii products; life ... See more keywords
Clinical outcome and adherence rate in Scandinavian patients with intermediate‐intensity prophylaxis before and after the switch of standard half‐life FVIII products to BAY 81–8973
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14489
Abstract: Treatment optimization in haemophilia A can be achieved by choice of FVIII product and knowledge of pharmacokinetics (PK), phenotype and adherence. A favourable PK profile of BAY 81–8973 (octocog alfa) (Kovaltry, Bayer AB) compared to… read more here.
Keywords: bay 8973; fviii products; half life; standard half ... See more keywords
A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2020.20199
Abstract: BACKGROUND Patients with hemophilia A are commonly treated with replacement recombinant factor VIII (rFVIII) products, which can be standard-acting or long-acting. Long-acting products have modifications, offering the potential for reduced dosing frequency while maintaining therapeutic… read more here.
Keywords: fviii products; long acting; rviii singlechain; bay ... See more keywords
Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice
Sign Up to like & getrecommendations! Published in 2018 at "Patient preference and adherence"
DOI: 10.2147/ppa.s151812
Abstract: Objectives To gain insights into the usage of factor VIII (FVIII) products by patients diagnosed with moderate/severe hemophilia A, and to assess the impact and perceived importance of product storage. Methods In this study, 200… read more here.
Keywords: storage; fviii products; impact; product choice ... See more keywords
Immune Responses to Plasma-Derived Versus Recombinant FVIII Products
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.591878
Abstract: The most severe side effect of hemophilia treatment is the inhibitor development occurring in 30% of patients, during the earliest stages of treatment with factor (F)VIII concentrates. These catastrophic immune responses rapidly inactivate the infused… read more here.
Keywords: inhibitor; fviii products; treatment; fviii ... See more keywords